Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.54 |
| ▸ | ACVR1B | P36896 | 10/20 | 0.54 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426265 | 0.90 | NUDT1 (0.55) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL2200023 | 0.88 | TGFBR1 (0.51) | TGFBR1ACVR1BACVRL1NUDT1ACVR1 | |
| SCHEMBL2201787 | 0.87 | TGFBR1 (0.53) | TGFBR1ACVR1BACVRL1NUDT1ACVR1 | |
| SCHEMBL5410649 | 0.82 | TGFBR1 (0.46) | TGFBR1ACVR1BACVRL1NUDT1ACVR1 | |
| SCHEMBL8344363 | 0.80 | TGFBR1 (0.63) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL3827835 | 0.79 | TGFBR1 (0.59) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL12426207 | 0.79 | TGFBR1 (0.57) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL2206244 | 0.79 | TGFBR1 (0.57) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL8344359 | 0.79 | TGFBR1 (0.59) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 | |
| SCHEMBL2494080 | 0.78 | TGFBR1 (0.57) | TGFBR1ACVR1BACVRL1CYP3A4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223766-B2 | Bi-cyclic pyrimidine inhibitors of TGFβ | SCIOS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | TGFBR1 3900/4885ACVR1B 4070/4885ACVRL1 4546/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | TGFBR1 3/4885ACVR1B 29/4885ACVRL1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.